aTyr Pharma plans June 2026 IND for new Phase 3 efzofitimod sarcoidosis trial

• aTyr Pharma mapped out a new global Phase 3 trial for efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, following FDA Type C meeting minutes reviewing prior Phase 3 EFZO-FIT results.
• EFZO-FIT results have already been presented to FDA; next pivotal study will test whether efzofitimod can slow loss of lung function while improving patient-reported symptoms, without citing detailed measurements.
• IND submission targeted for June 2026; trial designed as randomized, double-blind, placebo-controlled study enrolling up to 372 patients, with dosing moved to every three weeks to increase drug exposure.
• Primary readout will focus on lung function change at week 48; key secondary will assess symptom and quality-of-life improvement, with study duration set at 54 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111601PRIMZONEFULLFEED9717585) on May 11, 2026, and is solely responsible for the information contained therein.